Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CD80 antibody

This anti-CD80 antibody is a Human Monoclonal antibody detecting CD80 in ELISA and BR. Suitable for Human.
Catalog No. ABIN7072689

Quick Overview for Recombinant CD80 antibody (ABIN7072689)

Target

See all CD80 Antibodies
CD80

Antibody Type

Recombinant Antibody

Reactivity

  • 181
  • 96
  • 45
  • 6
  • 6
  • 6
  • 1
  • 1
  • 1
Human

Host

  • 104
  • 98
  • 20
  • 16
  • 11
  • 1
  • 1
Human

Clonality

  • 167
  • 81
  • 2
Monoclonal

Conjugate

  • 101
  • 21
  • 18
  • 16
  • 10
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
This CD80 antibody is un-conjugated

Application

  • 129
  • 94
  • 71
  • 35
  • 35
  • 23
  • 14
  • 13
  • 13
  • 12
  • 11
  • 10
  • 7
  • 5
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
ELISA, Blocking Reagent (BR)

Clone

16C10
  • Purpose

    Anti-CD80 [16C10], Human IgG1, lambda

    Specificity

    This antibody binds human CD80 and inhibits the B7.1:CD28 pathway.

    Characteristics

    Original Species of Ab: Rhesus Macaque

    Original Format of Ab: IgG1

    Purification

    Protein A affinity purified

    Immunogen

    This antibody was generated by immunization of cynomolgus monkeys with human B7.1 antigen.

    Isotype

    IgG1 lambda
  • Application Notes

    This antibody can be used for identification of human B7.1 antigen and is capable of inhibiting the binding of B7.1 to CD28, however it does not block the binding of B7.1 to CTLA-4. This antibody further inhibits the production of IL-2. Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. The binding of the antibody to soluble B7.1 was tested using ELISA. This antibody tested positive for binding to human C1q protein. This antibody is reported to cause keratinocyte hyperproliferation and decrease in psoriasis by inhibiting the B7:CD28 pathway. This antibody is further reported to be useful for the treatment of intestinal inflammation and rheumatoid arthritis.

    Restrictions

    For Research Use only
  • Concentration

    1 mg/mL

    Buffer

    PBS with 0.02 % Proclin 300.

    Preservative

    ProClin

    Precaution of Use

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Storage Comment

    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target

    CD80

    Alternative Name

    CD80

    Background

    B7.1, CD28L, CD28LG, B7-1, B7, BB1, B7/BB1,T-lymphocyte activation antigen CD80, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CTLA4L, CTLA-4L

    UniProt

    P33681

    Pathways

    TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
You are here:
Chat with us!